Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Income towards Parent Company (2017 - 2026)

Verrica Pharmaceuticals has reported Income towards Parent Company over the past 6 years, most recently at -$9.7 million for Q1 2026.

  • For Q1 2026, Income towards Parent Company rose 3.22% year-over-year to -$9.7 million; the TTM value through Mar 2026 reached -$18.7 million, up 70.63%, while the annual FY2025 figure was -$19.0 million, 74.3% up from the prior year.
  • Income towards Parent Company for Q1 2026 was -$9.7 million at Verrica Pharmaceuticals, down from -$8.3 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $1.5 million in Q3 2022 and troughed at -$24.8 million in Q3 2023.
  • A 5-year average of -$11.3 million and a median of -$10.0 million in 2025 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: surged 111.81% in 2022 and later tumbled 1733.8% in 2023.
  • Year by year, Income towards Parent Company stood at -$5.9 million in 2022, then tumbled by 316.02% to -$24.6 million in 2023, then soared by 45.01% to -$13.6 million in 2024, then surged by 38.76% to -$8.3 million in 2025, then fell by 16.54% to -$9.7 million in 2026.
  • Business Quant data shows Income towards Parent Company for VRCA at -$9.7 million in Q1 2026, -$8.3 million in Q4 2025, and -$308000.0 in Q3 2025.